Stockscreener 앱 받기
0.5836
1.08%
-0.0064
시간 외 거래:
.58
-0.0036
-0.62%
전일 마감가:
$0.59
열려 있는:
$0.587
하루 거래량:
1.54M
Relative Volume:
0.68
시가총액:
$98.02M
수익:
$15.93M
순이익/손실:
$-64.59M
주가수익비율:
-0.7781
EPS:
-0.75
순현금흐름:
$-59.50M
1주 성능:
-16.03%
1개월 성능:
+1.13%
6개월 성능:
-10.46%
1년 성능:
-38.80%
1일 변동 폭
$0.5702
$0.604
1주일 범위
$0.5702
$0.725
52주 변동 폭
$0.45
$1.42
Veru Inc Stock (VERU) Company Profile
명칭
Veru Inc
전화
(312) 595-9123
주소
2916 N. MIAMI AVENUE, MIAMI, FL
VERU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
0.5836 | 98.02M | 15.93M | -64.59M | -59.50M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-14 | 개시 | B. Riley Securities | Buy |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2023-06-07 | 업그레이드 | Jefferies | Underperform → Hold |
| 2021-04-13 | 개시 | Jefferies | Buy |
| 2021-02-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2018-07-03 | 개시 | Maxim Group | Buy |
모두보기
Veru Inc 주식(VERU)의 최신 뉴스
Veru (NASDAQ:VERU) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
Investors Purchase High Volume of Put Options on Veru (NASDAQ:VERU) - Defense World
Traders Buy High Volume of Put Options on Veru (NASDAQ:VERU) - MarketBeat
Upward Trajectory: Veru Inc (VERU) Posts a Slidee, Closing at 0.60 - DWinneX
Veru Inc. (NASDAQ:VERU) Stock Position Raised by Bank of America Corp DE - Defense World
VERU’s 2023 Market Dance: Up 6.22% – Time to Invest? - investchronicle.com
Veru to Participate in the Virtual BTIG Obesity Health Forum | V - GuruFocus
Veru to Participate in the Virtual BTIG Obesity Health Forum | VERU Stock News - GuruFocus
Veru Inc. to Engage with Investors at BTIG Obesity Health Forum on June 18, 2025 - Nasdaq
Veru to Participate in the Virtual BTIG Obesity Health Forum - The Manila Times
Veru Inc.'s (NASDAQ:VERU) 28% Share Price Surge Not Quite Adding Up - simplywall.st
Jane Street Group LLC Raises Stock Position in Veru Inc. (NASDAQ:VERU) - Defense World
VERUProspectus Filed Pursuant to Rule 424(b)(5) (424b5) - mx.advfn.com
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8 - mx.advfn.com
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024 - mx.advfn.com
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter - mx.advfn.com
Is Veru Inc (NASDAQ: VERU) A Great Stock To Invest In? - Stocksregister
Cetera Investment Advisers Boosts Holdings in Veru Inc. (NASDAQ:VERU) - Defense World
Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - MSN
Veru Inc. (NASDAQ:VERU) Shares Sold by Northern Trust Corp - Defense World
Beyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vital Farms to leave - Seeking Alpha
Veru selects enobosarm 3mg dose for Phase 3 trials after positive study By Investing.com - Investing.com South Africa
Muscle-sparing obesity drug safe for Phase 3 trial, Veru says - BioPharma Dive
Veru selects enobosarm 3mg dose for Phase 3 trials after positive study - Investing.com Australia
Veru Reports Positive Safety Results From Phase 2B Quality Study - marketscreener.com
Veru Reports Positive Safety Results from Phase 2b QUALITY Study - GuruFocus
Veru (VERU) Advances Enobosarm in Clinical Trials with Promising - GuruFocus
Veru’s enobosarm shows increased fat loss, muscle preservation and safety - TipRanks
Veru, GameStop, Azul - TradingView
Veru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with Semaglutide - Nasdaq
Veru Reports Positive Safety Results from Phase 2b QUALITY - GlobeNewswire
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone - Yahoo Finance
Veru (VERU) Advances Enobosarm in Clinical Trials with Promising Safety Data | VERU Stock News - GuruFocus
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom - Seeking Alpha
B. Riley Forecasts Veru's Q4 Earnings (NASDAQ:VERU) - MarketBeat
B. Riley Analysts Decrease Earnings Estimates for Veru - Defense World
MPM Bioimpact LLC Acquires New Shares in Veru Inc. (NASDAQ:VERU) - MarketBeat
Veru Target of Unusually Large Options Trading (NASDAQ:VERU) - Defense World
Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial - MSN
Veru (NASDAQ:VERU) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Barclays PLC Acquires 21,738 Shares of Veru Inc. (NASDAQ:VERU) - Defense World
Veru Inc. (NASDAQ:VERU) Stake Raised by Wells Fargo & Company MN - Defense World
Veru Inc. (NASDAQ:VERU) Q2 2025 Earnings Call Transcript - Insider Monkey
Veru Inc. Reports Progress in Clinical Trials and Financials - TipRanks
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ... - Yahoo Finance
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ... By GuruFocus - Investing.com Canada
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial Challenges - GuruFocus
Earnings call transcript: Veru Inc. beats Q2 2025 EPS forecast, stock rises - Investing.com India
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress - GlobeNewswire
Veru Q2 2025 Earnings Call Transcript - MarketBeat
Veru Inc. Earnings Call: Promising Results Amid Challenges - TipRanks
Veru Inc (VERU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Veru Inc 주식 (VERU) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rankowitz Michael L | Director |
Feb 19 '25 |
Buy |
0.58 |
54,721 |
31,919 |
250,000 |
1.45%
0.86%
자본화:
|
볼륨(24시간):